Background. A 13-valent pneumococcal conjugate vaccine (PCV13) seems to be associated with a reduction of community-acquired pneumonia (CAP) in children.
Pneumococcal conjugate vaccines (PCVs) implementation has been associated with significant reduction of invasive pneumococcal diseases, including community-acquired pneumonia (CAP) [1] [2] [3] [4] . For instance, the United States and Australia reported a decline in hospitalizations for CAP that ranged from 17% to 32% among children under 4 years of age [1, 2] . Among children aged < 5 years old, a 13% to 19% reduction was also reported in Canada [3] . The impact of 13-valent PCV (PCV13) on pleural effusion seemed greater (−50%) [1] . In France, an observational study carried out in pediatric emergency departments (EDs) reported a 16% decrease of CAP (32% for infants) between pre-and post-PCV13 periods. The proportion of CAP with C-reactive protein values >120 mg/L, used as a proxy of BP, also declined [4] .
To explore the trend of children visits for pneumonia in southern France EDs, before and after PCV13 implementation, we analyzed the mandatory Electronic Emergency Department Abstracts (EEDA), directly available from the patients' computerized medical files, from 2009 to 2014. This data source allowed an easy replication of the analysis over time and an adjustment on confusing factors, such as viral respiratory diseases.
METHODS
In France, EEDAs have been mandatory since 2014 for every patient admitted in an ED, and they are anonymously transmitted to the French Institute of Public Health Surveillance for syndromic surveillance [5] . In particular, EEDAs report the date of the visit, the age of the patient, if the patient is admitted or discharged, and the final diagnosis. Since 2008, the ED Observatory of Provence-Alpes-Côte d'Azur province (ORUPACA) collects these data for the southeastern region of the country (55 ED). The number of EDs who transmitted EEDAs to the ORUPACA has grown over time from 23 in 2009 to 55 in mid-2015. Final diagnosis related to the ED visits in the region have always been reported using the same selection of the International Classification Diseases (ICD-10) codes. This selection had been validated by the French Society of Emergency Medicine, and it did not vary during the period of our study.
For the collection of data, we selected the 7 EDs that had constantly reported EEDA from 2009 to 2014, had coded more than 90% of the final diagnosis, and had no significant change in missing values for diagnosis during the period. Three were pediatric EDs. All ICD codes included in the selection and related to pneumonia were retained to define CAP visits. The ICD codes were aggregated to define "bacterial pneumonia" ([BP] ICD codes J13, J14, J153, J156, J159, J170), "viral pneumonia" ([VP] ICD codes B012, B052, J100, J129, J171), and "nonspecific pneumonia" ([NSP] ICD code J189). The ICD codes related to Mycoplasma pneumoniae respiratory infections, which represented 1.8% of all CAP, were not included in the analysis, because diagnosis assays for this infection (real-time polymerase chain reaction) were not available in all centers during the entire period. To avoid bias relative to the increase of the number of visits during the study period (+4.5%), we used the proportion of pneumonia per 1000 visits.
For comparison with other observational French studies [4] , only children aged 1 month to 15 years were included, and we To compare the proportion of CAP, BP, VP, and NSP between different periods, we used a logistic regression analysis with the pre-PCV13 period as reference. To compare our results with the recent observational French study [4] , we have only presented the comparison between the pre-and early post-PCV13 periods (others comparisons are noted in the figure).
To evaluate possible coding bias related to change in the whole EEDA system, we tested several control conditions (ie, visits for another purpose, coded in the EEDA, and whose variations over time would have been very unlikely related to PCV13 implementation) with the same process. Pneumonia and pneumococcal pneumonia incidence may vary with common and seasonal viral outbreaks (such as flu or respiratory syncytial virus infection) [6] . Almost all previous studies did not take into account these confusing factors. To strengthen the potential causal link between PCV13 and pneumonia incidence, we proposed an adjustment on 2 major viral diseases causing pneumonia: bronchiolitis and influenza. Their proportions were defined as the ratio between the number of visits coded bronchiolitis or influenza and the total number of visits. Their cumulative proportion, thereafter called "respiratory viral infection" (RVI) proportion, was defined by the ratio between the number of visits coded bronchiolitis plus visits coded influenza and the total number of visits. For this analysis, data were aggregated at a daily level. The correlation between bronchiolitis, influenza, and RVI in one hand and CAP, BP, and NSP in the other hand was evaluated using the Pearson product-moment correlation coefficient. A general linear model was then used with daily proportion of BP as dependent variable, period (pre-PCVT13, early post-PCV13) as fixed factor, and daily proportion of RVI as covariate. P < .05 was considered statistically significant.
RESULTS
During the study period, 718 758 children were admitted in the 7 EDs, and CAP (7284 visits) represented 10.1/1000 admissions. Nonspecific pneumonia, BP, and VP represented 59.5%, 30.6%, and 7.9% of the CAP, respectively.
The evolution of CAP, BP, VP, NSP, and control conditions is presented Figure 1. A nonsignificant 2.0% decrease of all visits for CAP was observed between pre-PCV13 (10.11/1000) and early post-PCV13 (9.91/1000) periods. By age class, the decrease was 11.01% for infants under 2 years old (11.12 vs 9.98 per 1000; P = .12) and 13.10% for children aged 2 to 5 years (17.21 vs 14.96 per 1000; P = .02). A significant increase in visits for CAP among children aged 5 to 15 years (5.54 vs 7.36 per 1000; P < .001) was noted. For BP, a 51.9% decrease was observed (5.17 vs 2.49 per 1000; P < .001; odds ratio, 0.48; 95% confidence interval, 0.42-0.55) whatever the age, but it was more important in the youngest children (−58.4% among children <2 years, −61.8% between 2 and 5 years, and −28.87% between 5 and 15 years). The decrease of BP was also lasting during the late post-PCV13 period (2.27/1000 visits).
No significant change of the proportion of VP was observed between pre-and post-PCV13 periods (0.70 vs 0.81 per 1000 visits). In contrast, a 56.1% increase in NSP-coded CAP was observed between the 2 periods (4.24 to 6.62 per 1000 visits). The proportion of hospitalized CAP decreased by 16.0% between pre-PCV13 and early post-PCV13 periods (3.9 vs 3.2 per 1000; P = .01), and it was also higher in the youngest children: −21.4% among children <2 years old (5.2 vs 4.0 per 1000; P < .04) and −26.4% among children aged 2 to 5 years (6.0 vs 4.4 per 1000; P < .01).
On daily aggregated data, the correlation between the proportion of visits for flu or bronchiolitis and CAP, BP, or NSP was significant (Figure 2 ). The highest correlation was reported between CAP and bronchiolitis (Pearson's R = 0.506; P < .001). The proportion of RVI significantly correlated with CAP (R = .560) and was lower during the early post-PCV13 period compared with the pre-PCV13 (2.66 vs 2.37 per 1000; P < .001). However, using the general linear model for adjustment on RVI, the proportion of BP was still lower during the early post-PCV13 period than during the pre-PCV13 period (estimated marginal means: 5.10 vs 2.52 per 1000; P < .001).
The impact of PCVs on pneumococcal pneumonia is challenging. However, the diagnosis of pneumococcal pneumonia is not easy. Chest x-ray findings are not specific for any bacteria or virus, blood cultures are infrequently positive, and antigens tests for Streptococcus pneumoniae do not separate pneumococcal disease and pneumococcal nasopharyngeal carriage. Trends in visits for severe pneumonia, ie, pneumonia with high C-reactive protein value or hospitalized ones, are then used to compare pre-and post-PCV periods, considering severity as a hallmark of pneumococcal infection [4] . Data from ED have been used more and more in the syndromic surveillance system (SSS) [7] . It has been used to assess the impact of vaccination program for rotavirus [8] and, in adults, for pneumonia [9] .
Using EEDA, we exhaustively reported all the visits coded as CAP among children < 15 years in the included ED. Moreover, we ensured consistency of the results by focusing on the 7 ED with the lowest rates of missing values during the study period.
As expected [2] [3] [4] , the main finding of our study is the dramatic 52% decrease in BP after PCV13 implementation. In 2010, France experienced a universal pneumococcal vaccination switch from PCV7 to PCV13. However, the PCV coverage (whatever the vaccine) was constantly >90% in the country. The important decrease observed in BP in the study could be related to the fact that, in the pre-PCV13 period in France, the 6 additional PCV13 serotypes accounted for 90% of pneumococcal serotypes isolated in children pneumonia and empyema [4] .
The hospitalization rate for all CAP decreased as well (−16%). The global rate of 38% of hospitalization among CAP is consistent with the other French study [4] , and it reflects a stringent approach to treating pneumonia in France with frequent chest x-ray use for diagnosis.
The reduction in BP was more important in children <5 years (−60%), as previously shown. It could be related to a lower risk of CAP in oldest children, as suggested by the reduced frequency of half, observed in children aged 5-15 years compared with those under 2 years (5.54/1000 visits vs 11.12/1000), in the pre-PCV13 period.
In the present study, similar others [3, 4] , NSP increased. The interpretation of this trend can be confusing. Bacterial diagnosis of pneumonia in ED is often based on clinical signs of severity and a few biological markers, such as C-reactive protein or procalcitonin. A change in clinical decision rules for coding BP seems unlikely during the study period. However, a decrease of severe clinical presentations could have induced a diagnosis coding change from BP to NSP.
To support the claim of a vaccination impact on BP and not a change in the ED system, we evaluated the trend of control conditions whose prevalence is not expected to vary with PCV13. The selection of these controls is questionable, but the observed variations were not as dramatic and as deep as BP, or they were expected (biannual variation for laryngitis, for instance, has been previously reported [10, 11] ).
In a previous French observational study [4] , the authors concluded a strong efvaccine program in the provincfect of PCV13 on CAP without arguing causality criteria: association or causation [12] ? They also did not have adjusted data. It has been reported that the trend of infectious diseases showed temporal variations independently of vaccination or public health programs [13, 14] . Moreover, it is challenging to assess the impact of vaccination after adjustment on several other events that can affect the evolution or the notification of the disease. To increase the level of causal evidence between the decrease of CAP and the introduction of PCV13, we proposed the adjustment on 2 major viral illnesses causing pneumonia. Although visits for pneumonia and visits for bronchiolitis or influenza were correlated, the adjustment on these viral infections did not change the significance of the BP decrease.
There are some biases in the study. The 7 selected EDs were not representative of all regional EDs, because of the overrepresentation of pediatric ED for instance, but their choice (constant reporting, few missing data) allowed a consistency in the results. Similar to other observational series [4] , we cannot rule out selection bias if clinical practices, guidelines, availability of diagnosis tests, or the way of coding changed over the study period. We know that the selection of codes for EEDA did not change. Because diagnosis of pneumonia is based on chest x-rays in France, discrepancies in radiographic findings may be seen between emergency physicians and radiologists. However, it also seems unlikely that these variations would have changed during the study period.
CONCLUSIONS
In conclusion, ED data in southern France suggest a reduction in pediatric BP and hospitalized CAP after PCV13 implementation. Unlike the prospective observational study, the use of SSS allows completeness of the data with time. However, the sensitivity of this system has to be assessed. 
